Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin J Solomon

Showing results (21-30 of 129) with videos related to

Pageof 13
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 10, 2023
Antibody-Drug Conjugates for Lung Cancer: Payloads and ProgressSamuel Rosner, Augusto Valdivia, Hui Jing Hoe, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2020
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancerWanyuan Cui, Fanny Franchini, Marliese Alexander, et al.
The Oncologist|March 21, 2019
Clinical Management of Adverse Events Associated with LorlatinibTodd M Bauer, Enriqueta Felip, Benjamin J Solomon, et al.
Journal of the National Cancer Institute|March 8, 2026
Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trialJennifer Rogers, Michael Michael, Jeanne Tie, et al.
Lung Cancer (Amsterdam, Netherlands)|May 28, 2020
Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancerBenjamin J Solomon, Elizabeth E Kim, Maria Winter, et al.
Cancers|June 18, 2020
TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient SurvivalDonald Freudenstein, Cassandra Litchfield, Franco Caramia, et al.
Plos One|December 15, 2015
A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial MinicellsBenjamin J Solomon, Jayesh Desai, Mark Rosenthal, et al.
The Oncologist|October 22, 2025
Kinetics and Management of Adverse Events Associated With Lorlatinib After 5 Years of Follow-Up in the CROWN StudyGeoffrey Liu, Benjamin J Solomon, Julien Mazieres, et al.
Lung Cancer (Amsterdam, Netherlands)|March 30, 2024
A pragmatic guide for management of adverse events associated with lorlatinibGeoffrey Liu, Julien Mazieres, Jan Stratmann, et al.
Clinical Lung Cancer|August 13, 2013
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerEamon M Berge, Xian Lu, Delee Maxson, et al.
Pageof 13

Showing results (21-30 of 129) with videos related to

Sort By:
Pageof 13
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 10, 2023
Antibody-Drug Conjugates for Lung Cancer: Payloads and ProgressSamuel Rosner, Augusto Valdivia, Hui Jing Hoe, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2020
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancerWanyuan Cui, Fanny Franchini, Marliese Alexander, et al.
The Oncologist|March 21, 2019
Clinical Management of Adverse Events Associated with LorlatinibTodd M Bauer, Enriqueta Felip, Benjamin J Solomon, et al.
Journal of the National Cancer Institute|March 8, 2026
Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trialJennifer Rogers, Michael Michael, Jeanne Tie, et al.
Lung Cancer (Amsterdam, Netherlands)|May 28, 2020
Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancerBenjamin J Solomon, Elizabeth E Kim, Maria Winter, et al.
Cancers|June 18, 2020
TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient SurvivalDonald Freudenstein, Cassandra Litchfield, Franco Caramia, et al.
Plos One|December 15, 2015
A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial MinicellsBenjamin J Solomon, Jayesh Desai, Mark Rosenthal, et al.
The Oncologist|October 22, 2025
Kinetics and Management of Adverse Events Associated With Lorlatinib After 5 Years of Follow-Up in the CROWN StudyGeoffrey Liu, Benjamin J Solomon, Julien Mazieres, et al.
Lung Cancer (Amsterdam, Netherlands)|March 30, 2024
A pragmatic guide for management of adverse events associated with lorlatinibGeoffrey Liu, Julien Mazieres, Jan Stratmann, et al.
Clinical Lung Cancer|August 13, 2013
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerEamon M Berge, Xian Lu, Delee Maxson, et al.
Pageof 13